Detalhe da pesquisa
1.
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Cancer Chemother Pharmacol
; 91(5): 413-425, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37010549
2.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Cancer Chemother Pharmacol
; 91(5): 361-373, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36840749